Document is current

Article History

Received: 13 January 2025

Accepted: 10 March 2025

First Online: 29 March 2025

Declarations

:

: Christopher Lübker is an employee and shareholder of Novo Nordisk A/S. Jigish Bhavsar is an employee of Novo Nordisk Inc. and shareholder of Novo Nordisk A/S. Ruben Duque do Vale is an employee and shareholder of Novo Nordisk A/S. Scott S. Emerson declares having received consulting honoraria from Amylyx, AstraZeneca, Avillion, Ayala, Bayer, BeiGene, Boehringer Ingelheim, 89 Bio, BioAge, BioAtla, Bristol Meyer Squibb, BridgeBio, Daiichi Sankyo, Denovo, Fore Therapeutics, GlaxoSmithKline, Inovio, Insmed, Ipsen, Karuna, Lilly, Lundbeck, Mirati, Moderna, Novartis, Novavax, Novo Nordisk, NSABP, Pfizer, Principia, Reata, Rebiotx, Roche, Sanofi, SOLVD, Sutro Biopharma, and TG Therapeutics. Emil Nørtoft is an employee of Novo Nordisk A/S. Jorge Plutzky declares having received consulting honoraria from Altimmune, Amgen, Esperion Therapeutics, Inc., Merck, MJH Life Sciences, Novartis, and Novo Nordisk and has received a grant, paid to his institution, from Boehringer Ingelheim. Geraint Roberts is an employee of HEOR Ltd., who received fees from Novo Nordisk A/S in relation to this study. Jens Magelund Tarp is an employee of Novo Nordisk A/S. A. Michael Lincoff declares having received research grants paid to his institution from AbbVie Inc., AstraZeneca, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., and Novartis and has served as a consultant for Akebia Therapeutics Inc, Alnylam Pharmaceuticals Inc., Ardelyx, Eli Lilly and Company, FibroGen, GlaxoSmithKline, Intarcia, Medtronic Vascular, Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk, Provention Bio, Entity, and ReCor Medical.

: The SELECT trial protocol was reviewed by national and institutional regulatory and ethical authorities in each participating country, and the trial was conducted at 804 sites across 41 countries. All patients provided written informed consent before beginning any trial-related activity. The SELECT study was conducted in line with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The present analysis did not require informed consent or institutional/ethical review board approval since the analysis does not report any new studies with human participants or animals performed by any of the authors and was based on the previously conducted clinical trial. Any clinical data were anonymized for the purpose of the study.